A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
KCP-330-009
Phase 2 other active
Quick answer
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) for Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL is a Phase 2 program (other) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Karyopharm Therapeutics
- Indication
- Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL
- Phase
- Phase 2
- Modality
- other
- Status
- active